Trial · NCT02307526
Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI
NCT02307526, Phase 2, Completed, James J. Peters Veterans Affairs Medical Center; results first posted 2017-07-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI. Trials, record NCT02307526. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02307526
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI
- NCT number
- NCT02307526
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- James J. Peters Veterans Affairs Medical Center
- Conditions
- Hypotension, Postural
- Interventions
- Pyridostigmine Bromide, Tilt table test
- First posted
- 2014-12-04
- Last updated
- 2017-07-21
- Results first posted
- 2017-07-21
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Systolic Blood Pressure | Average systolic blood pressure of 10 minutes supine rest before pyridostigmine and after 45 minutes at 45 degrees after pyridostigmine administration compared to 10 minutes supine rest before tilt and at 45 degrees during no-drug head-up tilt maneuver. | |
| Primary | Diastolic Blood Pressure | Average diastolic blood pressure of 10 minutes supine rest before pyridostigmine and after 45 minutes at 45 degrees after pyridostigmine administration compared to 10 minutes supine rest before tilt and at 45 degrees during no-drug head-up tilt maneuver. | |
| Primary | Heart Rate | Average heart rate of 10 minutes supine rest before pyridostigmine and after 45 minutes at 45 degrees following pyridostigmine administration compared to 10 minutes supine rest before tilt and at 45 degrees during no-drug head-up tilt maneuver. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Systolic Blood Pressure | Average systolic blood pressure of 10 minutes supine rest before pyridostigmine and after 45 minutes at 45 degrees after pyridostigmine administration compared to 10 minutes supine rest before tilt and at 45 degrees during no-drug head-up tilt maneuver. | mm Hg | MEAN | |
| PRIMARY | Diastolic Blood Pressure | Average diastolic blood pressure of 10 minutes supine rest before pyridostigmine and after 45 minutes at 45 degrees after pyridostigmine administration compared to 10 minutes supine rest before tilt and at 45 degrees during no-drug head-up tilt maneuver. | mm Hg | MEAN | |
| PRIMARY | Heart Rate | Average heart rate of 10 minutes supine rest before pyridostigmine and after 45 minutes at 45 degrees following pyridostigmine administration compared to 10 minutes supine rest before tilt and at 45 degrees during no-drug head-up tilt maneuver. | bpm | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Systolic Blood Pressure | Pyridostigmine Bromide | Supine Systolic Blood Pressure | 97 | Standard Deviation 11 | mm Hg |
| Systolic Blood Pressure | NO Drug | Supine Systolic Blood Pressure | 103 | Standard Deviation 14 | mm Hg |
| Systolic Blood Pressure | Pyridostigmine Bromide | 45 degree Head-up Tilt Systolic Blood Pressure | 90 | Standard Deviation 18 | mm Hg |
| Systolic Blood Pressure | NO Drug | 45 degree Head-up Tilt Systolic Blood Pressure | 88 | Standard Deviation 12 | mm Hg |
| Diastolic Blood Pressure | Pyridostigmine Bromide | Supine Diastolic Blood Pressure | 64 | Standard Deviation 6 | mm Hg |
| Diastolic Blood Pressure | NO Drug | Supine Diastolic Blood Pressure | 66 | Standard Deviation 10 | mm Hg |
| Diastolic Blood Pressure | Pyridostigmine Bromide | 45 degree Head-up Tilt Diastolic Blood Pressure | 64 | Standard Deviation 11 | mm Hg |
| Diastolic Blood Pressure | NO Drug | 45 degree Head-up Tilt Diastolic Blood Pressure | 63 | Standard Deviation 7 | mm Hg |
| Heart Rate | Pyridostigmine Bromide | Supine Heart Rate | 52 | Standard Deviation 6 | bpm |
| Heart Rate | NO Drug | Supine Heart Rate | 55 | Standard Deviation 10 | bpm |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Day 1 - No Drug | STARTED | Spinal Cord Injury | 10 | |
| Day 1 - No Drug | COMPLETED | Spinal Cord Injury | 10 | |
| Day 1 - No Drug | NOT COMPLETED | Spinal Cord Injury | 0 | |
| Day 2 - 60 mg of Pyridostigmine | STARTED | Spinal Cord Injury | 10 | |
| Day 2 - 60 mg of Pyridostigmine | COMPLETED | Spinal Cord Injury | 10 | |
| Day 2 - 60 mg of Pyridostigmine | NOT COMPLETED | Spinal Cord Injury | 0 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Drug Side Effect | Nervous system disorders | Day 1 - No Drug | 0 | 10 | 0 |
| serious | Drug Side Effect | Nervous system disorders | Day 2 - Pyridostigmine Bromide | 1 | 10 | 1 |
| serious | Overheating | Nervous system disorders | Day 1 - No Drug | 0 | 10 | 0 |
| serious | Overheating | Nervous system disorders | Day 2 - Pyridostigmine Bromide | 1 | 10 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Day 1 - No Drug | ||
| Total, all-cause mortality | Day 2 - Pyridostigmine Bromide | ||
| Total, other adverse events | Day 1 - No Drug | 0 | 10 |
| Total, other adverse events | Day 2 - Pyridostigmine Bromide | 0 | 10 |
| Total, serious adverse events | Day 1 - No Drug | 0 | 10 |
| Total, serious adverse events | Day 2 - Pyridostigmine Bromide | 2 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Day 1 - No Drug vs Day 2 - Pyridostigmine Bromide: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02307526
GET https://conductscience.org/api/trials/v1/NCT02307526/registered